Cerus Corporation Awarded $1.4 Million to Advance Development of Pathogen Inactivation for Red Blood Cells

Published: Sep 23, 2010

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that it has received an additional $1.4 million from the U.S. Department of Defense to support advanced development of the company’s pathogen inactivation technology for red blood cells. The INTERCEPT red blood cell system is a pathogen inactivation product Cerus is developing to prevent the transmission of infectious diseases through red blood cell transfusions.

Back to news